FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2020

View the entire original 990 at ProPublica ↗

Organization: FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
Tax period: 2020-01-01 to 2020-12-31
Filed: 2021-11-02
IRS object ID: 202133069349300908
Schema version: 2020v4.1
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2021-11-02T07:44:36-05:00	ReturnTs
Tax Period End	2020-12-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	560747981	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	DIXON HUGHES GOODMAN LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	901 EAST CARY STREET SUITE 1000	AddressLine1Txt
City	RICHMOND	CityNm
State Abbreviation	VA	StateAbbreviationCd
ZIP	23219	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2020-01-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	521986675	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	FOUNDATION FOR THE NATIONAL INSTITUTES	BusinessNameLine1Txt
Business Name Line2	OF HEALTH INC	BusinessNameLine2Txt

Field	Value	IRS element (for citing)
Business Name Control	FOUN	BusinessNameControlTxt
Phone	3014025311	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 ROCKVILLE PIKE NO 600	AddressLine1Txt
City	NORTH BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	DONALD M HILL	PersonNm
Person Title	CHIEF FINANCIAL OFFICER	PersonTitleTxt
Phone	3014025311	PhoneNum
Signature	2021-10-26	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	DONALD	PersonFirstNm
Person Last	HILL	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	LAKRISHA J WATSON	PreparerPersonNm
PTIN	P01677333	PTIN
Phone	8042827636	PhoneNum
Preparation	2021-10-06	PreparationDt

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	2	TrustedCustomerCd
Authentication Assurance Level	AAL1	AuthenticationAssuranceLevelCd
Identity Assurance Level	IAL1	IdentityAssuranceLevelCd

Field	Value	IRS element (for citing)
Tax	2020	TaxYr
Build TS	2022-09-23 18:48:47Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	DONALD M HILL	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 ROCKVILLE PIKE NO 600	AddressLine1Txt
City	NORTH BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$215,637,725	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	HTTP://WWW.FNIH.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1996	FormationYr
Legal Domicile State	MD	LegalDomicileStateCd
Activity Or Mission	THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND MANAGES ALLIANCES WITH PUBLIC ANDPRIVATE INSTITUTIONS IN SUPPORT OF THE MISSION OF THE NIH, THE WORLD'S PREMIER MEDICAL RESEARCH AGENCY. THE FOUNDATION, ALSO KNOWN AS THE FNIH, WORKS WITH ITS PARTNERS TO ACCELERATE BIOMEDICAL RESEARCH AND STRATEGIES AGAINST DISEASES AND HEALTH CONCERNS IN THE UNITED STATES AND ACROSS THE GLOBE. THE FNIH ORGANIZES AND ADMINISTERS RESEARCH PROJECTS; SUPPORTS EDUCATION AND TRAINING OF NEW RESEARCHERS; ORGANIZES EDUCATIONAL EVENTS AND SYMPOSIA; AND ADMINISTERS A SERIES OF FUNDS SUPPORTING A WIDE RANGE OF HEALTH ISSUES. ESTABLISHED BY CONGRESS IN 1990, THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION.	ActivityOrMissionDesc
Voting Members Governing Body	26	VotingMembersGoverningBodyCnt
Voting Members Independent	25	VotingMembersIndependentCnt
Total Employee	75	TotalEmployeeCnt
Total Volunteers	25	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$50,623,645	PYContributionsGrantsAmt
CY Contributions Grants	$98,343,956	CYContributionsGrantsAmt
PY Program Service Revenue	-$50,000	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$3,163,912	PYInvestmentIncomeAmt
CY Investment Income	$1,793,315	CYInvestmentIncomeAmt
PY Other Revenue	$81,334	PYOtherRevenueAmt
CY Other Revenue	$42,551	CYOtherRevenueAmt
PY Total Revenue	$53,818,891	PYTotalRevenueAmt
CY Total Revenue	$100,179,822	CYTotalRevenueAmt
PY Grants And Similar Paid	$34,101,314	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$23,094,805	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$9,981,336	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$11,036,676	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$24,000	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$213,544	CYTotalFundraisingExpenseAmt
PY Other Expenses	$23,317,958	PYOtherExpensesAmt
CY Other Expenses	$24,522,875	CYOtherExpensesAmt
PY Total Expenses	$67,424,608	PYTotalExpensesAmt
CY Total Expenses	$58,654,356	CYTotalExpensesAmt
PY Revenues Less Expenses	-$13,605,717	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$41,525,466	CYRevenuesLessExpensesAmt
Total Assets BOY	$135,541,703	TotalAssetsBOYAmt
Total Assets EOY	$171,939,741	TotalAssetsEOYAmt
Total Liabilities BOY	$17,031,413	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$10,735,525	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$118,510,290	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$161,204,216	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$51,086,040	ExpenseAmt
Grant	$22,332,809	GrantAmt
Revenue	$0	RevenueAmt
Desc	SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)IN A YEAR TURNED UPSIDE-DOWN BY THE COVID-19 PANDEMIC, THE WORLD LOOKED TO SCIENCE FOR ANSWERSAND THE FNIH WAS A LEADER IN ACCELERATING THE SEARCH FOR SOLUTIONS. CONVENING AND DIRECTING THE ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) PUBLIC-PRIVATE PARTNERSHIP IN APRIL 2020, THE FNIH HAS SUPPORTED AND GUIDED THE EFFORTS OF MULTIPLE U.S. GOVERNMENT AGENCIES, NONPROFIT ORGANIZATIONS AND INDUSTRY PARTNERS, ALL WORKING TOGETHER TO DEVELOP COVID-19 VACCINES AND TREATMENTS.WITH HUNDREDS OF POTENTIAL THERAPEUTIC INTERVENTIONS UNDER CONSIDERATION, MANY OF THEM INITIATED BY RESEARCH INSTITUTIONS IN SMALL, UNDERPOWERED, NON-RANDOMIZED TRIALS, A FIRST ORDER OF BUSINESS WAS TO IDENTIFY AND FOCUS CRITICAL RESOURCES ON THE MOST PROMISING CANDIDATES. ACTIV SIFTED THROUGH HUNDREDS OF POTENTIAL THERAPEUTIC CANDIDATES TO PRIORITIZE THOSE MOST SUITABLE FOR CLINICAL DEVELOPMENT AND THEN HELPED DEVELOP A ROBUST, CENTRALIZED SUITE OF "MASTER PROTOCOL" CLINICAL TRIALS SPONSORED BY NIH AND FUNDED BY OPERATION WARP SPEED, IN WHICH TO TEST THEM. MASTER PROTOCOLS ALLOW RESEARCHERS TO EVALUATE MULTIPLE TREATMENT OPTIONS AT ONCE AGAINST A SINGLE CONTROL ARM, MAKING TRIALS MUCH MORE EFFICIENT AND GETTING POTENTIALLY LIFESAVING TREATMENTS EVALUATED AT MULTIPLE HOSPITALS AND CLINICS MORE EFFECTIVELY. ACTIV WAS CRITICAL TO IDENTIFYING, PRIORITIZING AND STANDARDIZING THE RESOURCES NEEDED TO PERFORM PRECLINICAL TESTING ON PROMISING THERAPEUTIC AGENTS PRIOR TO TESTING IN HUMANS.ACTIV ALSO ENABLED VACCINE DEVELOPERS TO COLLABORATE IN THE DEVELOPMENT OF HARMONIZED PROTOCOLS FOR VACCINE EFFICACY TRIALS SO THAT FINDINGS COULD BE MORE EASILY COMPARED AND ASSISTED FDA IN UNDERSTANDING THE REQUIREMENTS FOR EARLY USE AUTHORIZATIONS FOR THESE VACCINES. IN CONCERT WITH GOVERNMENT AND COMPANY EFFORTS, ACTIV PLAYED AN IMPORTANT SUPPORTING ROLE IN THE DEVELOPMENT OF COVID-19 VACCINES IN A BREATHTAKING 11 MONTHS, COMPARED WITH THE TEN YEARS OR MORE OFTEN REQUIRED.THE SCALE AND SPEED OF THE ACTIV COLLABORATION IS UNPRECEDENTED, AND IN CONVENING IT THE FNIH HELPED ITS PARTNERS RISE TO MEET THE URGENT NEED TO ADDRESS THE GLOBAL PANDEMIC. USING ITS DEEP EXPERIENCE IN MANAGING PUBLIC-PRIVATE RESEARCH PARTNERSHIPS, THE FNIH QUICKLY BROUGHT TOGETHER THE PEOPLE AND ORGANIZATIONS WITH THE RIGHT KNOWLEDGE, ABILITIES AND VIEWPOINTS TO ADDRESS THIS GLOBAL PUBLIC HEALTH EMERGENCY AND PROVIDED AN ENVIRONMENT TO FACILITATE THEIR COMBINED KNOWLEDGE. ACTIV HAS DEMONSTRATED THAT WE CAN INDEED MAKE RAPID PROGRESS TO ADDRESS COVID-19AS WELL AS THE OTHER BIOMEDICAL CHALLENGES OF OUR ERABY WORKING TOGETHER IN THE RIGHT PARTNERSHIP FRAMEWORK.GENECONVENEMALARIA REMAINS ONE OF THE WORLD'S DEADLIEST DISEASES, KILLING SOME 400,000 PEOPLEPRIMARILY YOUNG CHILDRENEVERY YEAR. MALARIA IS BOTH PREVENTABLE AND TREATABLE, YET STUBBORNLY PERSISTENT, IN PART BECAUSE CONTROL EFFORTS SUCH AS INSECTICIDE-TREATED MOSQUITO NETS, INDOOR RESIDUAL SPRAYING AND SEASONAL CHEMOPREVENTION REQUIRE SUBSTANTIAL FINANCIAL COMMITMENT, POLITICAL SUPPORT AND DAY-TO-DAY BEHAVIOR CHANGE AMONG INDIVIDUALS AND HOUSEHOLDS.NEW GENETIC BIOCONTROL TECHNOLOGIES COULD MAKE IT POSSIBLE TO REDUCE THE TOLL OF MALARIA EITHER BY REDUCING THE REPRODUCTION OF MALARIA-CARRYING MOSQUITOES, SO FEWER WILL BE PRESENT TO SPREAD DISEASE, OR BY DECREASING THEIR ABILITY TO CARRY THE MALARIA PARASITE. WITH MOSQUITOES NO LONGER TRANSMITTING MALARIA, INDIVIDUALS WOULD BE FREE OF SPECIAL PROTECTION MEASURES AND COMMUNITIES WOULD ENJOY EXTRAORDINARY SOCIAL, ECONOMIC AND HEALTH BENEFITS.IT'S AN INSPIRING YET CHALLENGING VISION, RAISING IMPORTANT TECHNICAL, REGULATORY AND ETHICAL QUESTIONS. AND WHILE THE SCIENTIFIC COMMUNITY HAS ESTABLISHED PROCEDURES FOR EVALUATING TOOLS LIKE VACCINES, MEDICINES AND INSECTICIDES, SUCH PROCEDURES HAVE NOT YET BEEN DEVELOPED FOR GENETIC BIOCONTROL. THAT'S WHY IN 2020 THE FNIH LAUNCHED THE GENECONVENE GLOBAL COLLABORATIVE, AN INITIATIVE TO ADVANCE THE SAFE AND RESPONSIBLE EXPLORATION OF GENETIC BIOCONTROL TECHNOLOGIES. BUILDING ON MORE THAN A DECADE OF FNIH WORK, GENECONVENE BRINGS TOGETHER SCIENTISTS, REGULATORS, POLICYMAKERS AND OTHER STAKEHOLDERS TO DEVELOP BEST PRACTICES AND ENSURE THAT GENETIC BIOCONTROL RESEARCH ADDRESSES IMPORTANT PUBLIC HEALTH PRIORITIES ETHICALLY, SAFELY AND EFFECTIVELY.GENECONVENE ALSO SERVES AS A GLOBAL HUB FOR RELEVANT, TIMELY AND ACCURATE KNOWLEDGE. A KEY RESOURCE FOR THIS WORK IS THE GENECONVENE VIRTUAL INSTITUTE, ALSO LAUNCHED IN 2020. THE VIRTUAL INSTITUTE IS AN ONLINE LIBRARY HOUSING SCHOLARLY LITERATURE, POLICY PAPERS, OPINION PIECES, EDUCATIONAL VIDEOS AND MEDIA COVERAGE. GENECONVENE ALSO HOSTS REGULAR WEBINARS THAT PROVIDE DIVERSE, MULTIDISCIPLINARY PERSPECTIVES ON THE SCIENTIFIC, SOCIAL AND ETHICAL DIMENSIONS OF GENETIC BIOCONTROL TECHNOLOGIES.REALIZING THE IMMENSE PROMISE OF GENETIC BIOCONTROL RESEARCH TO END MALARIA AND OTHER MOSQUITO-BORNE DISEASES OVER THE LONG TERM WILL REQUIRE A RIGOROUS EVALUATION OF THE RISKS AND BENEFITS OF EACH STEP ALONG THE WAY, FROM THE LABORATORY TO FIELD TESTING TO POTENTIAL IMPLEMENTATION. THROUGH THE GENECONVENE GLOBAL COLLABORATIVE, FNIH IS COMMITTED TO ENSURING THAT EVERYONE CHARGED WITH MAKING DECISIONS ABOUT GENETIC BIOCONTROLFROM SCIENTISTS TO POLICYMAKERS TO COMMUNITIESHAS THE KNOWLEDGE THEY NEED TO MOVE FORWARD SAFELY AND ETHICALLY.A-PLUS TRIALEVERY YEAR GLOBALLY, MORE THAN TWO MILLION BABIES DIE SHORTLY AFTER BIRTH, WHILE NEARLY 300,000 WOMEN DIE FROM PREVENTABLE CAUSES RELATED TO PREGNANCY AND CHILDBIRTH. MANY OF THESE DEATHSABOUT 10 PERCENT OF MATERNAL MORTALITY AND ABOUT 16 PERCENT OF NEONATAL MORTALITYARE CAUSED BY INFECTION, AND MANY OCCUR IN LOW- AND MIDDLE-INCOME COUNTRIES. DESPITE THE WIDESPREAD AVAILABILITY OF ANTIBIOTICS, THERE HAS BEEN LITTLE RECENT PROGRESS IN REDUCING THIS TOLL.IN 2020, THE FNIH ANNOUNCED THE LAUNCH OF A NEW INITIATIVE TO ADVANCE RESEARCH ON A SIMPLE BUT INNOVATIVE INTERVENTION THAT COULD BE A GAME-CHANGER FOR PREVENTING MATERNAL AND NEWBORN DEATH. LAUNCHED IN PARTNERSHIP WITH THEEUNICE KENNEDY SHRIVERNATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, THE MULTI-SITE EFFICACY AND SAFETY TRIAL OF INTRAPARTUM AZITHROMYCIN IN LOW- AND MIDDLE-INCOME COUNTRIES, ALSO CALLED THE A-PLUS STUDY, WILL ASSESS HOW WELL A SINGLE ORAL DOSE OF AZITHROMYCIN DURING LABOR CAN PROTECT THE HEALTH OF BOTH MOTHERS AND NEWBORNS.RECENT PRELIMINARY TRIALS OF PROVIDING AZITHROMYCIN DURING LABOR IN THE U.S. AND THE GAMBIA HAVE SHOWN PROMISING RESULTS, BUT A MUCH LARGER STUDY IS NEEDED TO CONFIRM THESE FINDINGS. THE A-PLUS TRIAL WILL ENROLL 34,000 WOMEN ACROSS SOUTH ASIA, SUB-SAHARAN AFRICA AND CENTRAL AMERICA. IF THE RESULTS OF THIS LARGE, THREE-YEAR TRIAL SHOW THAT PROPHYLACTIC TREATMENT LEADS TO FEWER INFECTIONS AND DEATHS, IT COULD INITIATE A TRANSFORMATION IN PRACTICE AT PARTICIPATING SITES AND NEW GUIDELINES FROM THE WORLD HEALTH ORGANIZATION AND OTHER PROFESSIONAL ORGANIZATIONS, POTENTIALLY SAVING THE LIVES OF MOTHERS AND BABIES AROUND THE WORLD.ACCELERATING MEDICINES PARTNERSHIP IN SCHIZOPHRENIA (AMP SCZ)SCHIZOPHRENIA, WHICH AFFECTS APPROXIMATELY 20 MILLION PEOPLE WORLDWIDE, IS ONE OF THE BEST-0KNOWN YET LEAST-UNDERSTOOD BRAIN DISORDERS. SYMPTOMS OFTEN EMERGE DURING THE TEENAGE YEARS OR EARLY ADULTHOOD, BUT THIS SERIOUS MENTAL DISORDER IS USUALLY NOT DIAGNOSED UNTIL PSYCHOSIS OCCURS, WHICH MAY BE SEVERAL YEARS LATER. DIAGNOSING AND TREATING SCHIZOPHRENIA SOONER COULD HELP YOUNG PEOPLE STRUGGLING WITH ITS EARLY SYMPTOMS AND POTENTIALLY DELAY OR STOP DISEASE PROGRESSION.THE FNIH'S ACCELERATING MEDICINES PARTNERSHIP IN SCHIZOPHRENIA (AMP SCZ), LAUNCHED IN SEPTEMBER 2020, AIMS TO IDENTIFY EARLY INDICATORS OF THE DISEASE, WHICH WILL ALLOW RESEARCHERS TO TEST NEW TREATMENTS THAT COULD DIAGNOSE AND HELP PATIENTS IN ITS INITIAL STAGES. THIS FIVE-YEAR, $99 MILLION PROJECT BRINGS TOGETHER NINE PARTNERS, INCLUDING GOVERNMENT AGENCIES, INDUSTRY, PRIVATE FOUNDATIONS AND PATIENT-CENTERED NOT-FOR-PROFIT ORGANIZATIONS, TO COLLABORATE IN THIS CRITICAL WORK. TOGETHER, THE PARTNERS ARE:- ESTABLISHING TWO RESEARCH NETWORKS CONNECTING OVER 40 U.S. AND INTERNATIONAL SITES WORKING WITH INDIVIDUALS AT HIGH RISK, ALLOWING IMPROVED COORDINATION AND ENHANCING APPLICABILITY OF RESULTS TO GLOBAL POPULATIONS- SUPPORTING RAPID ANALYSIS AND DISSEMINATION OF DATA THROUGH A STATE-OF-THE-SCIENCE DATA PROCESSING CENTER AND THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) DATA ARCHIVE, ALLOWING THE BROADER BIOMEDICAL RESEARCH COMMUNITY OPEN ACCESS AND EXTENDING THE REACH AND IMPACT OF THE WORK	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$1,062,478	ExpenseAmt
Grant	$761,996	GrantAmt
Revenue	$0	RevenueAmt
Desc	SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - INVESTING IN THE FUTURE OF SCIENTIFIC LEADERSHIP ONE OF THE MANY WAYS THE FNIH ACCELERATES PROGRESS IS THROUGH INVESTMENT IN THE CREATIVITY OF EXCEPTIONAL SCIENTISTS. THE ORGANIZATION BESTOWS THREE PRIZES EACH YEAR TO RECOGNIZE OUTSTANDING PARTNERS AND CONTRIBUTORS TO ADVANCING BIOMEDICAL RESEARCH. LURIE PRIZE IN BIOMEDICAL SCIENCELURIE PRIZE IN BIOMEDICAL SCIENCES IS AN ANNUAL PRIZE MADE POSSIBLE BY A GENEROUS GIFT FROM PHILANTHROPIST ANN LURIE, RECOGNIZING OUTSTANDING ACHIEVEMENTS MADE BY A PROMISING YOUNG SCIENTIST. IN 2020, THE FNIH HONORED AVIV REGEV, PH.D., FOR HER GROUNDBREAKING WORK DEVELOPING THE FIELD OF SINGLE-CELL GENOMICS. AT THAT TIME, DR. REGEV WAS CORE MEMBER, CHAIR OF THE FACULTY AND DIRECTOR OF THE KLARMAN CELL OBSERVATORY AT THE BROAD INSTITUTE OF MIT AND HARVARD.DR. REGEV'S WORK SPEARHEADING NEW TECHNOLOGIES THAT ENABLE A SHARPER PERSPECTIVE ON HUMAN CELLS HAS LED TO KEY INSIGHTS ABOUT HOW CELLS FUNCTION AND HAS REVOLUTIONIZED OUR UNDERSTANDING OF BIOLOGY AND DISEASES, INCLUDING CANCER AND AUTOIMMUNE DISORDERS.DR. REGEV IS A CO-FOUNDER AND CO-LEADER OF THE HUMAN CELL ATLAS, AN INTERNATIONAL COMMUNITY OF MORE THAN 1,800 SCIENTISTS WORKING TO CREATE COMPREHENSIVE REFERENCE MAPS OF ALL HUMAN CELLS. SHE IS CURRENTLY EXECUTIVE VICE PRESIDENT OF GENENTECH RESEARCH AND EARLY DEVELOPMENT.TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE TRAILBLAZER PRIZE WAS ESTABLISHED IN 2018 TO HIGHLIGHT THE ESSENTIAL ROLE OF EARLY CAREER CLINICIAN-SCIENTISTS IN SPURRING INNOVATION IN PATIENT CARE.IN 2020, MICHAEL WILSON, M.D., ASSOCIATE PROFESSOR OF NEUROLOGY IN THE DIVISION OF NEUROIMMUNOLOGY AND GLIAL BIOLOGY AT THE UCSF WEILL INSTITUTE FOR NEUROSCIENCES, WAS AWARDED THE PRIZE FOR PIONEERING A NEXT-GENERATION DIAGNOSTIC APPROACH TO PINPOINT INFECTIOUS CAUSES OF INFLAMMATORY CONDITIONS OF THE CENTRAL NERVOUS SYSTEM.DR. WILSON'S INNOVATIVE TECHNIQUE OF METAGENOMIC NEXT-GENERATION SEQUENCING ALLOWS PRECISE IDENTIFICATION OF THE SPECIFIC INFECTIOUS AGENTS CAUSING INFLAMMATION IN A PATIENT, WHILE RULING OUT IRRELEVANT PATHOGENS THAT MIGHT OTHERWISE HAVE BEEN SUSPECTED. USING THIS APPROACH, DR. WILSON HAS UNEARTHED KEY KNOWLEDGE ABOUT THE INFECTIOUS AND AUTOIMMUNE CAUSES OF INFLAMMATORY CONDITIONS IN THE BRAIN, SPINAL CORD AND MENINGES, INCLUDING MAJOR DISCOVERIES SUCH AS CO-IDENTIFYING THE FAMILY OF VIRUSES BEHIND ACUTE FLACCID MYELITIS, A PARALYZING, POLIO-LIKE CONDITION AFFECTING CHILDREN. FUNDING FOR THE TRAILBLAZER PRIZE IS PROVIDED BY THE GALLIN FUND AT THE FNIH.CHARLES A. SANDERS, M.D., PARTNERSHIP AWARDEACH YEAR, THE FNIH BESTOWS THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RECOGNIZE PEOPLE AND/OR ORGANIZATIONS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE ORGANIZATION'S EFFORTS TO BUILD, IMPLEMENT AND NURTURE PUBLIC-PRIVATE PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH.IN 2020, THE FNIH HONORED ANTHONY S. FAUCI, M.D., LONG-TIME DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID), FOR HIS LEGACY OF LEADERSHIP AND ONGOING SUPPORT OF FNIH PROGRAMS PROPELLING RESEARCH IN LETHAL INFECTIOUS DISEASES, MOST RECENTLY FOR COVID-19.AS NIAID DIRECTOR SINCE 1984, DR. FAUCI HAS BEEN AT THE FOREFRONT OF THE SCIENTIFIC RESPONSE TO PREVENT, DIAGNOSE AND TREAT THE WORLD'S MOST VEXING INFECTIOUS DISEASES, INCLUDING HIV/AIDS, ZIKA, EBOLA AND MANY OTHERS. OVER THE COURSE OF HIS EXTENSIVE CAREER, DR. FAUCI HAS OVERSEEN A WIDE VARIETY OF RESEARCH COLLABORATIONS BETWEEN NIAID AND THE FNIH, INCLUDING WORK IN AFRICA ON HIV/AIDS, AS WELL AS TUBERCULOSIS VACCINES, TREATMENTS AND BIOINFORMATICS. HE CURRENTLY SERVES ON THE EXECUTIVE COMMITTEE OF THE FNIH-COORDINATED ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) INITIATIVE, A PUBLIC-PRIVATE PARTNERSHIP TO EXPEDITE DEVELOPMENT OF VACCINES AND TREATMENTS FOR COVID-19.FUNDING FOR THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD IS PROVIDED BY THE CHARLES A. SANDERS LEGACY FUND AT THE FNIH.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$54,582	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -FILLING A NEED OF THE NATION'S LEADING RESEARCH CENTERAT THE NIH CLINICAL CENTER THE NATION'S PREMIER HOSPITAL SOLELY DEVOTED TO CLINICAL INVESTIGATION PATIENTS ARE CONSIDERED "ACTIVE PARTNERS IN MEDICAL DISCOVERY," PARTICIPATING IN EXPERIMENTAL TRIALS CARRIED OUT BY NIH INSTITUTES TO RECEIVE TREATMENT FOR THEIR CONDITIONS AND ULTIMATELY BENEFIT SCIENTIFIC PROGRESS. THE EXTENSIVE LIST OF RESEARCH BREAKTHROUGHS COMING OUT OF THE NIH CLINICAL CENTER INCLUDES THE FIRST CURES FOR CHILDHOOD LEUKEMIA AND HODGKIN'S DISEASE USING CHEMOTHERAPY, THE FIRST BLOOD TESTS FOR AIDS AND HEPATITIS, AND THE FIRST GENE THERAPY, TO NAME JUST A FEW. TO SUPPORT SUCH RESOURCE-INTENSIVE ENDEAVORS, THE FNIH ESTABLISHED THE CLINICAL CENTER IN-KIND DRUG DONATION PROGRAM TO DONATE PHARMACEUTICALS TO THE NIH CLINICAL CENTER. THE PROGRAM, WHICH HAS PROVIDED NEARLY $16 MILLION IN DRUGS AND THERAPEUTICS TO THE NIH SINCE 2008, WAS SUPPORTED IN 2019 BY A MAJOR GIFT FROM HORIZON THERAPEUTICS PLC. "THE GENEROSITY OF THE PROGRAM HAS BEEN A MAJOR BOON TO OUR PATIENTS AND OUR PROGRAM," SAYS DR. STEVEN HOLLAND, DIRECTOR, DIVISION OF INTRAMURAL RESEARCH AT NIAID.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$52,203,100	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	Yes (1)	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	Yes (1)	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	35	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	75	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (1)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (1)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	26	GoverningBodyVotingMembersCnt
Independent Voting Member	25	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	DONALD M HILL	PersonNm
Phone	3014356246	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	11400 ROCKVILLE PIKE SUITE 600	AddressLine1Txt
City	NORTH BETHESDA	CityNm
State Abbreviation	MD	StateAbbreviationCd
ZIP	20852	ZIPCd

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	Yes (X)	InfoInScheduleOPartVIIInd

Form990 Part VII Section A Form990PartVIISectionAGrp (41 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
DR STEVEN M PAUL
CHAIRMAN	1.50	Yes (X)	Yes (X)	$0	$0	$0
DR SOLOMON H SNYDER
VICE-CHAIRMAN	0.50	Yes (X)	Yes (X)	$0	$0	$0
MR STEVEN C MAYER
TREASURER	2.00	Yes (X)	Yes (X)	$0	$0	$0
MRS WILLIAM MCCORMICK BLAIR JR
SECRETARY	1.00	Yes (X)	Yes (X)	$0	$0	$0
DR MARIA C FREIRE
PRESIDENT AND EXECUTIVE DIRECTOR	40.00	Yes (X)	Yes (X)	$516,856	$0	$31,250
DR KATHY BLOOMGARDEN
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MRS WILLIAM N CAFRITZ
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR MARIJN DEKKERS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR JAMES H DONOVAN
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR PAUL L HERRLING
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR THOMAS R INSEL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR JUDY LANSING KOVLER
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR RONALD L KRALL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR FREDA C LEWIS-HALL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
JULIE BELL LINDSAY
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR EDISON T LIU
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR JOEL S MARCUS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR PAUL M MONTRONE
BOARD OF DIRECTORS MEMBER UNTIL 5/20	0.50	Yes (X)		$0	$0	$0
DAME JILLIAN SACKLER
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MRS LILY SAFRA
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR CHARLES A SANDERS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR FRED SEIGEL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR ELLEN V SIGAL
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
MR RUSSELL W STEENBERG
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR PAUL STOFFELS
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
DR ELIAS ZERHOUNI
BOARD OF DIRECTORS MEMBER	0.50	Yes (X)		$0	$0	$0
GILBERT S OMENN
BOARD OF DIRECTORS MEMBER FROM 5/20	0.50	Yes (X)		$0	$0	$0
MR DONALD HILL
CHIEF FINANCIAL OFFICER	40.00		Yes (X)	$254,979	$0	$42,966
MR KEVIN A KLOCK
VP OF OPERATIONS & GENERAL COUNSEL	40.00		Yes (X)	$227,164	$0	$40,816
MR DAVID WHOLLEY
SENIOR VP OF RESEARCH PARTNERSHIPS	40.00			$373,754	$0	$45,750	Yes (X)
DR STEPHANIE JAMES
SENIOR VP OF SCIENCE	40.00			$351,650	$0	$28,500	Yes (X)
MICHAEL SANTOS
ASSOCIATE VICE PRESIDENT OF SCIENCE	40.00			$289,646	$0	$35,540	Yes (X)
MS JULIE WOLF-RODDA
SENIOR VP OF DEVELOPMENT	40.00			$235,610	$0	$39,835	Yes (X)
DR JOSEPH MENETSKI
ASSOCIATE VP OF RESEARCH PARTNERSHIPS	40.00			$235,372	$0	$39,381	Yes (X)
MR ROBERT BALTHASER
VICE PRESIDENT OF ADVANCEMENT	40.00			$166,026	$0	$23,484	Yes (X)
ABBEY MELTZER
VP OF COMMUNICATIONS AND EVENTS	40.00			$153,421	$0	$29,931	Yes (X)
DR STACEY ADAM
DIRECTOR OF CANCER RESEARCH PARTNERSHIPS	40.00			$191,762	$0	$26,100		Yes (X)
DR DAVID O'BROCHTA
SCIENTIFIC PROGRAM MANAGER	40.00			$188,311	$0	$34,874		Yes (X)
DR KAREN TOUNTAS
SCIENTIFIC PROGRAM MANAGER	40.00			$186,176	$0	$32,182		Yes (X)
BRINDA DASS
SCIENTIFIC PROGRAM MANAGER	40.00			$179,292	$0	$27,871		Yes (X)
STEVEN HOFFMANN
DIRECTOR OF INFLAMMATION & IMMNUNITY	40.00			$171,317	$0	$31,699		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,721,336	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$510,179	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	32	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SWOG CTI
24 FRANK LLOYD WRIGHT DRIVE PO BOX	ANN ARBOR	MI	48105	CONDUCTS CLINICAL TRIAL FOR LUNGMAP	$9,208,799
THE BROAD INSTITUTE INC
415 MAIN STREET	CAMBRIDGE	MA	02142	PROFESSIONAL SERVICES FOR THE AMP T2DIAB	$2,360,378
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUE	BOSTON	MA	02215	RESEARCH COLLABORATION AGREEMENT FOR THE	$2,253,477
DELOITTE CONSULTING LLP
4022 SELLS DRIVE	HERMITAGE	TN	37076	PROFESSIONAL SERVICES FOR THE ACCELARATI	$1,758,012
THE UNIVERSITY OF TEXASMD ANDERSON
PO BOX 4266	HOUSTON	TX	77210	RESEARCH COLLABORATION AGREEMENT FOR THE	$1,298,453

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	28	CntrctRcvdGreaterThan100KCnt
Fundraising	$72,000	FundraisingAmt
Government Grants	$1,250,000	GovernmentGrantsAmt
All Other Contributions	$97,021,956	AllOtherContributionsAmt
Noncash Contributions	$845,251	NoncashContributionsAmt
Total Contributions	$98,343,956	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,722,957	TotalRevenueColumnAmt
Exclusion	$1,722,957	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$115,312,812	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$115,242,454	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$70,358	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$70,358	TotalRevenueColumnAmt
Exclusion	$70,358	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$258,000	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$72,000	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$215,449	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$42,551	TotalRevenueColumnAmt
Exclusion	$42,551	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$100,179,822	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$1,835,866	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$20,919,453	TotalAmt
Program Services	$20,919,453	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$358,500	TotalAmt
Program Services	$358,500	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$1,816,852	TotalAmt
Program Services	$1,816,852	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,887,178	TotalAmt
Program Services	$1,208,525	ProgramServicesAmt
Management And General	$1,606,141	ManagementAndGeneralAmt
Fundraising	$72,512	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$6,264,915	TotalAmt
Program Services	$4,192,753	ProgramServicesAmt
Management And General	$2,009,872	ManagementAndGeneralAmt
Fundraising	$62,290	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$626,744	TotalAmt
Program Services	$379,706	ProgramServicesAmt
Management And General	$229,573	ManagementAndGeneralAmt
Fundraising	$17,465	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,053,496	TotalAmt
Program Services	$709,034	ProgramServicesAmt
Management And General	$315,615	ManagementAndGeneralAmt
Fundraising	$28,847	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$204,343	TotalAmt
Program Services	$278,153	ProgramServicesAmt
Management And General	-$73,810	ManagementAndGeneralAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$251,071	TotalAmt
Program Services	$135,891	ProgramServicesAmt
Management And General	$115,180	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$172,078	TotalAmt
Management And General	$172,078	ManagementAndGeneralAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$24,028	TotalAmt
Program Services	$13,944	ProgramServicesAmt
Management And General	$10,084	ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$17,849	TotalAmt
Program Services	$9,644	ProgramServicesAmt
Management And General	$8,175	ManagementAndGeneralAmt
Fundraising	$30	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$121,689	TotalAmt
Program Services	$35,000	ProgramServicesAmt
Management And General	$66,192	ManagementAndGeneralAmt
Fundraising	$20,497	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$738,820	TotalAmt
Program Services	$180,012	ProgramServicesAmt
Management And General	$558,808	ManagementAndGeneralAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$232,941	TotalAmt
Program Services	$218,432	ProgramServicesAmt
Management And General	$12,140	ManagementAndGeneralAmt
Fundraising	$2,369	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$250,896	TotalAmt
Management And General	$250,896	ManagementAndGeneralAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$192,613	TotalAmt
Program Services	$120,114	ProgramServicesAmt
Management And General	$72,499	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM CONTRACTS	$19,323,011	$19,323,011
CONSULTANTS	$3,863,288	$3,441,965	$421,323
RELOCATION	$339,228		$339,228
HONORARIA	$119,534	$110,000		$9,534

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	-$1,124,171	TotalAmt
Program Services	-$1,247,889	ProgramServicesAmt
Management And General	$123,718	ManagementAndGeneralAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$58,654,356	TotalAmt
Program Services	$52,203,100	ProgramServicesAmt
Management And General	$6,237,712	ManagementAndGeneralAmt
Fundraising	$213,544	FundraisingAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$33,010,960	BOYAmt
EOY	$66,486,739	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$11,954,468	BOYAmt
EOY	$41,358,911	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$248,256	BOYAmt
EOY	$235,751	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$2,948,307	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$999,474	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$1,574,395	BOYAmt
EOY	$1,948,833	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$88,147,149	BOYAmt
EOY	$59,636,280	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$606,475	BOYAmt
EOY	$2,273,227	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$135,541,703	BOYAmt
EOY	$171,939,741	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$10,145,693	BOYAmt
EOY	$7,166,950	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$5,147,362	BOYAmt
EOY	$1,331,478	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$1,738,358	BOYAmt
EOY	$2,237,097	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$17,031,413	BOYAmt
EOY	$10,735,525	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$21,577,974	BOYAmt
EOY	$25,368,465	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$96,932,316	BOYAmt
EOY	$135,835,751	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$118,510,290	BOYAmt
EOY	$161,204,216	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$135,541,703	BOYAmt
EOY	$171,939,741	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	$41,525,466	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$1,168,460	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Info In Schedule O Part XII	Yes (X)	InfoInScheduleOPartXIIInd
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$82,860,385	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$61,322,159	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$60,444,618	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,623,645	CurrentTaxYearMinus1YearAmt
Current Tax Year	$98,343,956	CurrentTaxYearAmt
Total	$353,594,763	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$82,860,385	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$61,322,159	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$60,444,618	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,623,645	CurrentTaxYearMinus1YearAmt
Current Tax Year	$98,343,956	CurrentTaxYearAmt
Total	$353,594,763	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$146,344,040	SubstantialContributorsTotAmt
Public Support Total170	$207,250,723	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$574,125	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,066,052	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$2,057,158	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$2,818,334	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,722,957	CurrentTaxYearAmt
Total	$8,238,626	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$361,833,389	TotalSupportAmt
Gross Receipts Rltd Activities	$248,775	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.57280	PublicSupportCY170Pct
Public Support PY170	0.56230	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	Yes (1)	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	0	MailingsMembersInd
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	0	GrantsOtherOrganizationsInd
Direct Contact Legislators	Yes (1)	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	0	OtherActivitiesInd
Total Lobbying Expenditures	$0	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1:	FormAndLineReferenceDesc
Explanation	FNIH CONSULTED ITS CONGRESSIONAL COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Donor Advised Funds Held	1	DonorAdvisedFundsHeldCnt
Donor Advised Funds Contri	$3,700	DonorAdvisedFundsContriAmt
Donor Advised Funds Grants	$22,444	DonorAdvisedFundsGrantsAmt
Donor Advised Funds Vl EOY	$234,886	DonorAdvisedFundsVlEOYAmt
Disclosed Org Leg Ctrl	Yes (1)	DisclosedOrgLegCtrlInd
Disclosed For Charitable Prps	Yes (1)	DisclosedForCharitablePrpsInd
Agent Trustee Etc	0	AgentTrusteeEtcInd
Incl Escrow Custodial Acct Liab	0	InclEscrowCustodialAcctLiabInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$14,897,505	BeginningYearBalanceAmt
Contributions	$5,648,998	ContributionsAmt
Investment Earnings Or Losses	$419,982	InvestmentEarningsOrLossesAmt
Administrative Expenses	$88,450	AdministrativeExpensesAmt
End Year Balance	$20,878,035	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$12,514,811	BeginningYearBalanceAmt
Contributions	$1,788,682	ContributionsAmt
Investment Earnings Or Losses	$705,900	InvestmentEarningsOrLossesAmt
Administrative Expenses	$111,888	AdministrativeExpensesAmt
End Year Balance	$14,897,505	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$11,920,726	BeginningYearBalanceAmt
Contributions	$1,032,217	ContributionsAmt
Investment Earnings Or Losses	-$267,231	InvestmentEarningsOrLossesAmt
Other Expenditures	$103,397	OtherExpendituresAmt
Administrative Expenses	$67,504	AdministrativeExpensesAmt
End Year Balance	$12,514,811	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,704,030	BeginningYearBalanceAmt
Contributions	$1,721,204	ContributionsAmt
Investment Earnings Or Losses	$552,828	InvestmentEarningsOrLossesAmt
Administrative Expenses	$57,336	AdministrativeExpensesAmt
End Year Balance	$11,920,726	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$9,501,571	BeginningYearBalanceAmt
Contributions	$11,412	ContributionsAmt
Investment Earnings Or Losses	$243,278	InvestmentEarningsOrLossesAmt
Administrative Expenses	$52,231	AdministrativeExpensesAmt
End Year Balance	$9,704,030	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.74475	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.25525	PrmnntEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,869,159	OtherCostOrOtherBasisAmt
Depreciation	$330,439	DepreciationAmt
Book Value	$1,538,720	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,079,148	OtherCostOrOtherBasisAmt
Depreciation	$669,035	DepreciationAmt
Book Value	$410,113	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$1,948,833	TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (3 entries)

DescDesc	AmtAmt
CHARITABLE GIFT ANNUITY	$125,764
DEFERRED LEASE INCENTIVE	$1,538,721
DEFERRED RENT LIABILITY	$572,612

Field	Value	IRS element (for citing)
Total Liability	$2,237,097	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$102,041,639	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$1,168,460	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$649,986	DonatedServicesAndUseFcltsAmt
Revenue Not Reported	$1,818,446	RevenueNotReportedAmt
Revenue Subtotal	$100,223,193	RevenueSubtotalAmt
Investment Expenses Not Incld	$172,078	InvestmentExpensesNotIncldAmt
Other Revenues Not Included	-$215,449	OtherRevenuesNotIncludedAmt
Revenue Not Reported Fincl Stmt	-$43,371	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$100,179,822	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$59,347,713	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$649,986	DonatedServicesUseFcltsAmt
Other Expenses Included	$215,449	OtherExpensesIncludedAmt
Expenses Not Reported	$865,435	ExpensesNotReportedAmt
Expenses Subtotal	$58,482,278	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$172,078	InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt	$172,078	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$58,654,356	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (4 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART V, LINE 4:	THE FOUNDATION HAS ONE ENDOWMENT THAT IS FUNDED BY MULTIPLE DONORS TO SEED NEW DISCOVERIES AND/OR BE AVAILABLE TO RESPOND TO EPIDEMICS AND FOUNDATION'S UNANTICIPATED NEEDS. THE FOUNDATION'S OTHER ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS.
PART X, LINE 2:	THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2020 AND 2019.
PART XI, LINE 4B - OTHER ADJUSTMENTS:	FUNDRAISING DIRECT EXPENSE -215,449.
PART XII, LINE 2D - OTHER ADJUSTMENTS:	FUNDRAISING DIRECT EXPENSE 215,449.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND)	GRANTMAKING	$878,719
EAST ASIA AND THE PACIFIC	GRANTMAKING	$39,477
SUB-SAHARAN AFRICA	GRANTMAKING	$898,656

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	0	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	0	TotalEmployeeCnt
Subtotal Spent	$1,816,852	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$1,816,852	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (7 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	RESEARCH	$229,325	WIRE TRANSFER
SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO,	RESEARCH	$227,449	WIRE TRANSFER
SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO,	RESEARCH	$671,207	WIRE TRANSFER
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA,	RESEARCH	$39,477	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	RESEARCH	$71,323	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	RESEARCH	$285,414	WIRE TRANSFER
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	RESEARCH	$292,657	WIRE TRANSFER

Field	Value	IRS element (for citing)
Total501c3 Org	1	Total501c3OrgCnt
Total Other Org	6	TotalOtherOrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 2:

PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS.

PART III ACCOUNTING METHOD:

Schedule G IRS990ScheduleG

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	2020 FNIH AWARD CEREMONY	Event1Nm
Gross Receipts Event1	$330,000	GrossReceiptsEvent1Amt
Charitable Contri Event1	$72,000	CharitableContriEvent1Amt
Gross Revenue Event1	$258,000	GrossRevenueEvent1Amt
Food And Beverage Event1	$303	FoodAndBeverageEvent1Amt
Other Direct Expenses Event1	$189,780	OtherDirectExpensesEvent1Amt
Event2	2021 FNIH AWARD CEREMONY	Event2Nm
Other Direct Expenses Event2	$25,366	OtherDirectExpensesEvent2Amt
Gross Receipts Total	$330,000	GrossReceiptsTotalAmt
Charitable Contributions Tot	$72,000	CharitableContributionsTotAmt
Gross Revenue Total Events	$258,000	GrossRevenueTotalEventsAmt
Food And Beverage Total Events	$303	FoodAndBeverageTotalEventsAmt
Oth Direct Expnss Total Events	$215,146	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$215,449	DirectExpenseSummaryEventsAmt
Net Income Summary	$42,551	NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (26 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
NIHCC - CLINICAL CENTER
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$409,444	RESEARCH
NIHNATIONAL INSTITUTE ON AGING
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$2,774,181	RESEARCH
NIHNCI
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$2,860,444	RESEARCH
NIHNIAID
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$3,216,529	RESEARCH
NIHNIAMS
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$3,533,808	RESEARCH
NIHNINDS
9000 ROCKVILLE PIKE	BETHESDA	MD	20892	520858115	170(C)(1) GOVT	$542,086	RESEARCH
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789 GENERAL POST OFFICE	NEW YORK	NY	100879789	135598093	501(C)(3)	$767,983	RESEARCH
TRUSTEES OF INDIANA UNIVERSITY
THE POPLARS BUILDING400 E SEVENTH	BLOOMINGTON	IN	474053085	356001673	501(C)(3)	$226,585	RESEARCH	ST
UNIVERSITY OF VIRGINIA
PO BOX 400195	CHARLOTTESVILLE	VA	22904	546001796	501(C)(3)	$240,083	RESEARCH
UNIVERSITY OF COLORADO DENVER
PO BOX 910238	DENVER	CO	80291	846000555	501(C)(3)	$215,016	RESEARCH
CASE WESTERN RESERVE UNIVERSITY
NORD HALL SUITE 615 10900 EUCLID	CLEVELAND	OH	44106	341018992	501(C)(3)	$539,772	RESEARCH	AVENUE
UNIVERSITY OF LOUISIANA AT LAFAYETTE
4401 W ADMIRAL DOYLE DRIVE	NEW IBERIA	LA	70560	726023836	501(C)(3)	$544,987	RESEARCH
DUKE UNIVHUMAN VACCINE INSTITUTE
2200 WEST MAIN STREET SUITE 820	DURHAM	NC	27705	560532129	501(C)(3)	$196,891	RESEARCH	ERWIN SQUARE PLAZA
FRED HUTCHINSON CANCER RESEARCH CTR
1100 FAIRVIEW AVE N	SEATTLE	WA	98109	237156071	501(C)(3)	$444,646	RESEARCH
CATALYSIS FOUNDATION FOR HEALTH INC
1900 POWELL STREET SUITE 600	EMERYVILLE	CA	94608	208602047	501(C)(3)	$238,789	RESEARCH
UNIVERSITY OF PITTSBURGH
200 LOTHROP ST BIOMEDICAL SCIENCE	PITTSBURGH	PA	15213	250965591	501(C)(3)	$343,422	RESEARCH	TOWER W 950
REGENTS OF THE UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET 1040	ANN ARBOR	MI	48109	386006309	501(C)(3)	$1,000,000	RESEARCH	WOLVERINE TOWER
TRUSTEE OF BOSTON UNIVERSITY FOR THE BOSTON UNIVERSITY MEDICAL SCHOOL
PO BOX 28763 GRANT RECEIVABLE	NEW YORK	NY	100878763	042103547	501(C)(3)	$150,000	RESEARCH
JOHNS HOPKINS UNIVERSITY
615 N WOLFE ST W1100	BALTIMORE	MD	21205	150595110	501(C)(3)	$30,000	RESEARCH
REGENTS OF THE UOF CALIFORNIASAN FRANCISCO
MISSION HALL 550 16TH STREET 2ND	SAN FRANCISCO	CA	94143	946036493	501(C)(3)	$27,576	RESEARCH	FLOOR
BRIGHAM & WOMEN'S HOSPITAL
1620 TREMONT STREET 3RD FLOOR RM BC	BOSTON	MA	02120	042312909	501(C)(3)	$232,921	RESEARCH	3002
FRIENDS OF CANCER RESEARCH
1800 M STREET NW SUITE 1050 SOUTH	WASHINGTON	DC	20036	521983273	501(C)(3)	$216,611	RESEARCH
UNIVERSITY OF SOUTHERN CALIFORNIA
SOTO STREET BUILDING 2001 SOTO	LOS ANGELES	CA	900899235	911642394	501(C)(3)	$1,150,000	RESEARCH	STREET
WESTERN MICHIGAN UNIVERSITY
1903 W MICHIGAN AVENUE	KALAMAZOO	MI	49008	386007327	501(C)(3)	$534,892	RESEARCH
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
446 N FIFTH STREET SUITE 600	PHOENIX	AZ	85005	331092191	501(C)(3)	$86,764	RESEARCH
LEIDOS BIOMEDICAL RESEARCH INC
1050 BOYLES STREET	FREDERICK	MD	21702	330653185		$396,023	RESEARCH AND DEVELOPMENT

Field	Value	IRS element (for citing)
Total501c3 Org	25	Total501c3OrgCnt
Total Other Org	1	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp

Field	Value	IRS element (for citing)
Grant Type	AWARDS	GrantTypeTxt
Recipient	11	RecipientCnt
Cash Grant	$358,500	CashGrantAmt
Valuation Method Used	FMV	ValuationMethodUsedDesc

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	0	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (15 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
DR MARIA C FREIRE
PRESIDENT AND EXECUTIVE DIRECTOR	$491,856	$0	$25,000	$0	$0	$0	$28,500	$0	$2,750	$0	$548,106	$0	$0	$0
MR DAVID WHOLLEY
SENIOR VP OF RESEARCH PARTNERSHIPS	$363,754	$0	$10,000	$0	$0	$0	$28,500	$0	$17,250	$0	$419,504	$0	$0	$0
DR STEPHANIE JAMES
SENIOR VP OF SCIENCE	$351,650	$0	$0	$0	$0	$0	$28,500	$0	$0	$0	$380,150	$0	$0	$0
MICHAEL SANTOS
ASSOCIATE VICE PRESIDENT OF SCIENCE	$289,646	$0	$0	$0	$0	$0	$28,500	$0	$7,040	$0	$325,186	$0	$0	$0
MR DONALD HILL
CHIEF FINANCIAL OFFICER	$249,979	$0	$5,000	$0	$0	$0	$25,666	$0	$17,300	$0	$297,945	$0	$0	$0
MS JULIE WOLF-RODDA
SENIOR VP OF DEVELOPMENT	$235,610	$0	$0	$0	$0	$0	$23,285	$0	$16,550	$0	$275,445	$0	$0	$0
DR JOSEPH MENETSKI
ASSOCIATE VP OF RESEARCH PARTNERSHIP	$232,872	$0	$2,500	$0	$0	$0	$23,616	$0	$15,765	$0	$274,753	$0	$0	$0
MR KEVIN A KLOCK
VP OF OPERATIONS & GENERAL COUNSEL	$222,164	$0	$5,000	$0	$0	$0	$23,066	$0	$17,750	$0	$267,980	$0	$0	$0
DR DAVID O'BROCHTA
SCIENTIFIC PROGRAM MANAGER	$188,311	$0	$0	$0	$0	$0	$18,824	$0	$16,050	$0	$223,185	$0	$0	$0
DR KAREN TOUNTAS
SCIENTIFIC PROGRAM MANAGER	$186,176	$0	$0	$0	$0	$0	$18,512	$0	$13,670	$0	$218,358	$0	$0	$0
DR STACEY ADAM
DIRECTOR OF CANCER RESEARCH PARTNERS	$191,762	$0	$0	$0	$0	$0	$19,160	$0	$6,940	$0	$217,862	$0	$0	$0
BRINDA DASS
SCIENTIFIC PROGRAM MANAGER	$179,292	$0	$0	$0	$0	$0	$18,181	$0	$9,690	$0	$207,163	$0	$0	$0
STEVEN HOFFMANN
DIRECTOR OF INFLAMMATION & IMMNUNITY	$171,317	$0	$0	$0	$0	$0	$17,149	$0	$14,550	$0	$203,016	$0	$0	$0
MR ROBERT BALTHASER
VICE PRESIDENT OF ADVANCEMENT	$166,026	$0	$0	$0	$0	$0	$16,544	$0	$6,940	$0	$189,510	$0	$0	$0
ABBEY MELTZER
VP OF COMMUNICATIONS AND EVENTS	$151,421	$0	$2,000	$0	$0	$0	$15,381	$0	$14,550	$0	$183,352	$0	$0	$0

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	3	ContributionCnt
Noncash Contributions Rpt F990	$845,251	NoncashContributionsRptF990Amt
Method Of Determining Revenues	STOCK PRICE	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (8 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED:	AMP SCZ IS THE FIFTH ACCELERATING MEDICINES PARTNERSHIP INITIATIVE, AND THE FIRST TO FOCUS ON A NEUROPSYCHIATRIC DISORDER. THESE TRAILBLAZING PARTNERSHIPS TRANSFORM THE CURRENT MODEL FOR DEVELOPING NEW DIAGNOSTICS AND TREATMENTS BY BRINGING TOGETHER THE RESOURCES OF NIH AND INDUSTRY TO IMPROVE OUR UNDERSTANDING OF DISEASE PATHWAYS AND FACILITATE BETTER SELECTION OF TARGETS FOR TREATMENT. OTHER AMP INITIATIVES ARE WORKING TO SPEED THE DEVELOPMENT OF NEW DIAGNOSTICS AND TREATMENTS FOR ALZHEIMER'S DISEASE, TYPE 2 DIABETES, RHEUMATOID ARTHRITIS/LUPUS AND PARKINSON'S DISEASE. PLASMA AB ALZHEIMER'S DISEASE IS AMONG THE LEADING CAUSES OF DEATH AMONG U.S. ADULTS. BECAUSE IT GRADUALLY IMPAIRS A PERSON'S THINKING AND SOCIAL SKILLS, ALZHEIMER'S DISEASE ALSO PLACES TREMENDOUS BURDENS ON THOSE LIVING WITH THE DISORDER AS WELL THEIR FAMILIES AND CAREGIVERS. DESPITE DECADES OF RESEARCH, THERE IS NO CURE FOR ALZHEIMER'S DISEASE AND ONLY A HANDFUL OF APPROVED TREATMENTS. THE AVAILABLE TREATMENTS CAN ALLEVIATE THE SYMPTOMS OF DISEASEBUT CANNOT STOP IT FROM CONTINUING TO DAMAGE THE BRAIN. SCIENTISTS ALSO NOW BELIEVE THAT ALZHEIMER'S DISEASE MAY BEGIN DECADES BEFORE OUTWARD SIGNS, SUCH AS MEMORY LOSS, BECOME APPARENT. IN MARCH 2020, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED A BOLD NEW PROJECTPLASMA A AS A PREDICTOR OF AMYLOID POSITIVITY IN ALZHEIMER'S DISEASEINTENDED TO IDENTIFY SIMPLE, EFFECTIVE TESTS TO DETECT EARLY ALZHEIMER'S DISEASE, PAVING THE WAY FOR POTENTIAL TREATMENTS THAT COULD STOP THE DISORDER BEFORE IT HAS SERIOUSLY DAMAGED THE BRAIN. THE NEW FNIH PROJECT BRINGS TOGETHER GOVERNMENT, ACADEMIC, NOT-FOR-PROFIT AND INDUSTRY EXPERTS TO COMPARE SIX DIFFERENT POTENTIAL PLATFORMS TO MEASURE BETA AMYLOID, OR ABETA, IN A PERSON'S BODY. DEPOSITS OF ABETA IN THE BRAIN CAUSE PLAQUES BETWEEN NERVE CELLS AND ARE THOUGHT TO PLAY A ROLE IN ALZHEIMER'S DISEASE. THE TESTS UNDER EVALUATION MEASURE LEVELS OF ABETA IN PLASMA, REQUIRING ONLY A SIMPLE BLOOD DRAW. THE GOAL OF THE PARTNERSHIP IS TO DETERMINE WHICH PLATFORMS FOR MEASURING ABETA IN BLOOD PLASMA CAN ACCURATELY PREDICT THE PRESENCE OF BETA AMYLOID IN THE BRAIN. AN ABETA BLOOD TEST COULD REPLACE CURRENT TOOLS FOR MEASURING BETA AMYLOID, SUCH AS PET SCANS OR TESTING OF CEREBROSPINAL FLUID, WHICH CAN BE INVASIVE, EXPENSIVE AND PAINFUL. THIS WOULD IMMEDIATELY MAKE CLINICAL TRIALS FOR ALZHEIMER'S DISEASE PREVENTION AND TREATMENT EASIER ON RESEARCHERS AND TRIAL VOLUNTEERS. OVER THE LONGER TERM, THE TEST COULD SPEED THE SEARCH FOR NEW TREATMENTS THAT TARGET THE DISEASE IN ITS EARLIEST STAGESSPARING MILLIONS OF AMERICANS FROM THE RISK OF IRREVERSIBLE BRAIN DAMAGE.
FORM 990, PART VI, SECTION A, LINE 1	THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS.
FORM 990, PART VI, SECTION B, LINE 11B	PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER.
FORM 990, PART VI, SECTION B, LINE 12C	DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS.
FORM 990, PART VI, SECTION B, LINE 15	THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE PRESIDENT AND EXECUTIVE DIRECTOR'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE PRESIDENT AND EXECUTIVE DIRECTOR AND RELATED COMPENSATION DECISIONS.
FORM 990, PART VI, SECTION C, LINE 19	ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE.
FORM 990, PART VII, SECTION A:	DONALD M. HILL AND KEVIN A. KLOCK WERE KEY EMPLOYEES THROUGH SEPTEMBER 2020 AND WERE RECLASSIFIED AS OFFICERS STARTING OCTOBER 2020.
FORM 990, PART XII, LINE 2C:	PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.